Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;103(11):4607-4612.
doi: 10.1007/s00277-024-05981-9. Epub 2024 Sep 9.

Safety of Rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin's lymphoma: a retrospective study

Nina K Song  1 , Hala Musa  1   2 , Michael Soriano  2 , David E Hibbs  1 , Iqbal Ramzan  1 , Jennifer A Ong  3
Affiliations

Safety of Rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin's lymphoma: a retrospective study

Nina K Song et al. Ann Hematol. 2024 Nov.

Abstract

Unlike small molecule drugs and generic products, the active component of biologics and biosimilars are not identical chemical entities. Despite bioequivalence, there is limited evidence in clinical practice (i.e. Phase IV post-marketing surveillance) regarding the safety of biosimilar rituximab and even less so for "switching therapy" with respect to safety. Drug substitution by switching aims to realise cost savings by changing therapy involving a reference (biologic) product to a biosimilar. A retrospective analysis of safety outcomes including treatment-emergent adverse effects (TEAEs), rates of death and discontinuation of therapy, for all patients that received switching therapy (from reference to biosimilar rituximab, n = 33) was compared to patients who did not did not switch therapy (received biosimilar rituximab only, n = 18) at an Australian metropolitan cancer centre, over a six-month period. There was no statistical significant differences for any safety outcomes examined. Switching therapy for patients receiving rituximab does not lead to poorer safety outcomes.

Keywords: Biosimilars; GP2013; Rituximab; Safety; Switching.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Diagram showing study arms
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. American Society of Clinical Oncology (ASCO) (2024) Lymphoma - Non-Hodgkin: Statistics. https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/statistics (accessed 2nd
    1. Cai W, Zeng Q, Zhang X, Ruan W Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990–2019: Results From the Global Burden of Disease Study 2019, (in English), Frontiers in Medicine, Original Research vol. 8, no. 1609, 2021-September-23 2021, 10.3389/fmed.2021.738693 - PMC - PubMed
    1. Dotan E, Aggarwal C, Smith MR (2010) Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin’s Lymphoma, (in eng), P & T: a peer-reviewed journal for formulary management, vol. 35, no. 3, pp. 148–157, [Online]. Available:https://pubmed.ncbi.nlm.nih.gov/20442809https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844047/ - PMC - PubMed
    1. Pfreundschuh M et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, (in eng), Lancet Oncol., vol. 7, no. 5, pp. 379 – 91, May 10.1016/s1470-2045(06)70664-7 - PubMed
    1. Tilly H et al (Sep 2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up, (in eng). Ann Oncol 26(5):v116–v125. 10.1093/annonc/mdv304 - PubMed

Substances

LinkOut - more resources